San Diego-based Kemia announced that it has raised $33.5M in a Series B, led by JPMorgan Partners. New investors Novo A/S and Hamilton Apex also participated, as well as all of the company's prior investors. Ron Ferguson of JPMorgan has also joined the company's board. Kemia is developing small molecule medicines targeted at inflammation, cancer, HIV, diabetes and bone diseases. More information »